ArticleEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2025
Miltefosine implementation for treatment of cutaneous leishmaniasis: access indicators in the state of Minas Gerais, 2021-2024.
Article in Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmaceutical services: opportunities and perspectives for generating scientific evidence.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe and evaluate the initial indicators of the pilot implementation of miltefosine in Minas Gerais for the treatment of cutaneous leishmaniasis.
methodsThis is a descriptive, cross-sectional study based on regulatory documents and secondary administrative data generated during the dispensing of miltefosine in Minas Gerais between May 2021 and April 2024. Indicators related to access and operability of the strategy implemented were calculated for the steps involved in approving the request for use and dispensing of the drug.
resultsThe authorization rate was 97.5% for 281 valid requests. The outpatient clinic of the René Rachou Institute, a reference center for leishmaniasis in Minas Gerais, was responsible for the largest number of requests during the period. The health macro-regions Centre and North concentrated the largest number of requests (48.9% and 33.6%), which coincided with the regions with the highest number of reported cases. Median time for analyzing requests and for the person to access the medicine was 1.0 (0-76) and 10.0 (0-340) days, with significant variation between the health macro-regions. One hundred and nineteen people were treated in a municipality other than their place of residence. Of these, 49 needed to travel to another health macro-region. The miltefosine diffusion rate was 11.3% for the three-year period monitored, with significant variation between the macro-regions.
conclusionThe indicators confirmed that miltefosine has been implemented, but revealed low diffusion and regional disparities. Barriers need to be identified and strategies developed to expand equitable access to new technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.